Recommendation of final dividend for the financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Smallcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories Board has recommended a final dividend of Rs. 34 per share (340% on face value of Rs. 10) for FY 2025-26. The company reported strong financial results with revenue from operations of Rs. 2,02,299 lakhs, up 37% from Rs. 1,47,684 lakhs in the previous year. Profit after tax stood at Rs. 36,310 lakhs (standalone), a significant jump from Rs. 25,943 lakhs. The profit before tax was Rs. 48,774 lakhs, boosted by an exceptional gain of Rs. 7,640 lakhs from transfer of investment property. EPS for the year was Rs. 283.01 per share. The record date for dividend eligibility is July 24, 2026, and the 42nd AGM will be held on August 4, 2026. Separately, the company approved capacity expansion of 120.5 KL at its Unit 1 facility with an investment of Rs. 143.4 crores.
The recommendation of a 340% dividend reflects strong profitability and cash generation, signaling confidence in the company's financial health. This should be positive for shareholder returns, though the high payout ratio may draw attention given the capital expansion plans.